NEW YORK, March 29, 2017 /PRNewswire/ -- The global human embryonic stem cells (hESCs) market is anticipated to reach USD 1.06 billion by 2025, according to a new report by Grand View Research, Inc. Application of hESCs as a promising donor source for cellular transplantation therapies is anticipated to bolster progress through to 2025. hESCs technology tends
Maintenance of developmental potential for contribution of derivatives of all three germ layers is an important feature of these cells. This ability remains consistent even after clonal derivation or prolonged undifferentiated proliferation, thus pronouncing its accelerated uptake. In addition, these are capable in expressing high level of alkaline phosphatase, key transcription factors, and telomerase. These factors are found to be of great importance in the maintenance of the inner cellular mass pluripotency. Furthermore, hESCs can be easily differentiated into defined neurons, neural lineages, oligodendrocytes, and astrocytes. Aforementioned characteristic makes it useful in studying the sequence of events that take place during early neurodevelopment.
However, use of stem cells derived from viable embryos is fraught with ethical issues, prompting scientists to explore other methods to generate ESCs. The other methods include derivation of embryonic germ cells, stem cells from dead embryos, and other techniques. Further Key Findings from the Report Suggest: hESC derivation provides a unique opportunity for early human development studies It is believed to hold a substantial potential for regenerative medicine and biopharma Differentiated derivatives of these cells are applicable for screening assays in development of novel pharmaceutical moieties Screening for mutagenic as well as toxic compounds can also be carried out using such derivatives Presence of lack of suitable donor organs and tissues for regenerative medicine is expected to increase the demand thus influencing growth Stem cell research is anticipated to exhibit fastest growth amongst the other applications However, presence of controversies pertaining to their use as a consequence of ethical considerations is responsible for steady growth Europe accounts for considerable share of the market, following North America As per a recent survey carried out by Swiss government, citizens there are more willing to accept embryonic stem cell research than politicians Asia Pacific is anticipated to drive market with fastest YoY growth Rising awareness amongst the population and physicians with respect to associated therapies is anticipated to propel progress Key players contributing in this market are CellGenix GmbH, International Stem Cell Corporation, Thermo Fisher Scientific, Inc.; Kite Pharma, PromoCell GmbH, and Lonza Presence of clinical trial pipeline for embryonic stem cell derived therapy for targeting different diseases is expected to fuel growth.
The diseases targeted include macular degeneration, Parkinson's disease, type I diabetes mellitus, and spinal cord injury.Read the full report: http://www.reportlinker.com/p04785473-summary/view-report.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com__________________________Contact Clare: [email protected]US: (339)-368-6001Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/human-embryonic-stem-cells-hesc-market-analysis-by-application-regenerative-medicines-stem-cell-biology-research-tissue-engineering-toxicology-testing-by-country-us-uk-germany-japan-china-and-segment-forecasts-20-300431401.html
Subscribe to our Free Newsletters!
Hand hygiene is a simple and affordable technique to prevent infections.
Erythropoietin is a hormone secreted by kidneys in response to low oxygen levels in tissues ...
Local anesthesia is a type of anesthesia generally used to block pain sensation only in a specific ...View All